Comparison of clinical and laboratory characteristics of patients with AML treated with HMA plus venetoclax stratified by occurrence of cardiac events
| All patients (n = 170) . | Cardiac complication (n = 34) . | No cardiac complication (n = 136) . | P . |
|---|---|---|---|
| Patient characteristics | |||
| Median age at venetoclax, y (range) | 69 (18-92) | 71 (40-91) | .09 |
| Age at venetoclax >60 y, no. (%) | 29 (85) | 107 (79) | .63 |
| Male gender, no. (%) | 21 (62) | 86 (63) | 1.0 |
| Cardiovascular risk factors, no. (%) | 30 (88) | 126 (93) | .3 |
| Pretreatment EF <50%, no. (%) | 10/32 (31) | 24/109 (22) | .29 |
| Median counts at diagnosis (range) | |||
| Hemoglobin, g/dL | 8.6 (6.9-13.6) | 8.4 (4.8-14) | .22 |
| Leukocyte count, ×109/L | 4.4 (0.5-112) | 3.7 (0.1-145) | .37 |
| Platelet count, ×109/L | 51 (5-239) | 57 (7-444) | .73 |
| AML subdiagnosis, no. (%) | .62 | ||
| AML, de novo | 18 (53) | 70 (51) | |
| AML, post-MDS | 10 (29) | 49 (36) | |
| AML, therapy-related | 6 (18) | 17 (13) | |
| Venetoclax treatment setting, no. (%) | |||
| Upfront | 23 (67) | 86 (63) | .69 |
| Relapsed/refractory | 11 (33) | 50 (37) | |
| HMA type, no. (%) | .62 | ||
| Azacitidine | 16 (47) | 47 (35) | |
| Decitabine | 18 (53) | 89 (65) | |
| Karyotype, no. (%) 2017 ELN risk stratification | .17 | ||
| Favorable | 3 (9) | 4 (3) | |
| Intermediate | 14 (41) | 68 (50) | |
| Adverse | 17 (50) | 64 (47) | |
| Genomics, no. (%) | |||
| DNMT3A/TET2/ASXL1 | 16 (47) | 49 (36) | .23 |
| DNMT3A | 2 (6) | 19 (14) | .38 |
| TET2 | 10 (30) | 22 (16) | .08 |
| ASXL1 | 7 (21) | 20 (15) | .43 |
| FLT3 | 5 (15) | 16 (12) | .56 |
| CEBPA | 4 (12) | 3 (2) | .03 |
| TP53 | 10 (30) | 34 (25) | .51 |
| EZH2 | 1 (3) | 7 (5) | 1 |
| IDH2/IDH1 | 4 (12) | 25 (18) | .68 |
| WT1 | 1 (3) | 6 (4) | 1 |
| RUNX1 | 5 (15) | 23 (17) | 1 |
| SRSF2 | 3 (9) | 21 (15) | .58 |
| NPM1 | 6 (18) | 16 (12) | .38 |
| Median overall survival, mo (95% CI) | 6 (3-17) | 16 (10-24) | <.001 |
| All patients (n = 170) . | Cardiac complication (n = 34) . | No cardiac complication (n = 136) . | P . |
|---|---|---|---|
| Patient characteristics | |||
| Median age at venetoclax, y (range) | 69 (18-92) | 71 (40-91) | .09 |
| Age at venetoclax >60 y, no. (%) | 29 (85) | 107 (79) | .63 |
| Male gender, no. (%) | 21 (62) | 86 (63) | 1.0 |
| Cardiovascular risk factors, no. (%) | 30 (88) | 126 (93) | .3 |
| Pretreatment EF <50%, no. (%) | 10/32 (31) | 24/109 (22) | .29 |
| Median counts at diagnosis (range) | |||
| Hemoglobin, g/dL | 8.6 (6.9-13.6) | 8.4 (4.8-14) | .22 |
| Leukocyte count, ×109/L | 4.4 (0.5-112) | 3.7 (0.1-145) | .37 |
| Platelet count, ×109/L | 51 (5-239) | 57 (7-444) | .73 |
| AML subdiagnosis, no. (%) | .62 | ||
| AML, de novo | 18 (53) | 70 (51) | |
| AML, post-MDS | 10 (29) | 49 (36) | |
| AML, therapy-related | 6 (18) | 17 (13) | |
| Venetoclax treatment setting, no. (%) | |||
| Upfront | 23 (67) | 86 (63) | .69 |
| Relapsed/refractory | 11 (33) | 50 (37) | |
| HMA type, no. (%) | .62 | ||
| Azacitidine | 16 (47) | 47 (35) | |
| Decitabine | 18 (53) | 89 (65) | |
| Karyotype, no. (%) 2017 ELN risk stratification | .17 | ||
| Favorable | 3 (9) | 4 (3) | |
| Intermediate | 14 (41) | 68 (50) | |
| Adverse | 17 (50) | 64 (47) | |
| Genomics, no. (%) | |||
| DNMT3A/TET2/ASXL1 | 16 (47) | 49 (36) | .23 |
| DNMT3A | 2 (6) | 19 (14) | .38 |
| TET2 | 10 (30) | 22 (16) | .08 |
| ASXL1 | 7 (21) | 20 (15) | .43 |
| FLT3 | 5 (15) | 16 (12) | .56 |
| CEBPA | 4 (12) | 3 (2) | .03 |
| TP53 | 10 (30) | 34 (25) | .51 |
| EZH2 | 1 (3) | 7 (5) | 1 |
| IDH2/IDH1 | 4 (12) | 25 (18) | .68 |
| WT1 | 1 (3) | 6 (4) | 1 |
| RUNX1 | 5 (15) | 23 (17) | 1 |
| SRSF2 | 3 (9) | 21 (15) | .58 |
| NPM1 | 6 (18) | 16 (12) | .38 |
| Median overall survival, mo (95% CI) | 6 (3-17) | 16 (10-24) | <.001 |